Oral fumurate research

A board to discuss future MS therapies in early stage (Phase I or II) trials.

Oral fumurate research

Postby bromley » Sat May 27, 2006 9:50 am

User avatar
bromley
Family Elder
 
Posts: 1887
Joined: Fri Sep 10, 2004 3:00 pm

Advertisement

Postby bromley » Tue May 30, 2006 11:08 am

Easier to read version of the above research. Doesn't look like a blockbuster to me given FTY720, which is another oral drug.

http://c.moreover.com/click/here.pl?j544029392&w=464753
User avatar
bromley
Family Elder
 
Posts: 1887
Joined: Fri Sep 10, 2004 3:00 pm

Postby bromley » Wed May 31, 2006 6:18 am

Biogen so liked the product they bought the company! They now have control over Avonex, Tysabri, oral fumarate, Daclizumab and Rituxan.

http://www.biogenidec.com/site/019_0.ht ... PR_129.htm
User avatar
bromley
Family Elder
 
Posts: 1887
Joined: Fri Sep 10, 2004 3:00 pm

Postby Loriyas » Wed May 31, 2006 6:37 am

This may not be such a bad thing. As a company they will not be marketing just one treatment for MS as the ONLY treatment. When the drug reps talk to the docs they will give them pros/cons of each treatment and the docs will be able to see advantages for different patients. They will cross-market these drugs to obtain more market share so the docs will hear the message more than once. This is a case of Biogen not putting "all of their eggs in one basket", knowing that different treatments work for different patients. Therefore, more choices for patients. Just a thought!

Lori
Loriyas
Family Elder
 
Posts: 583
Joined: Sun Apr 02, 2006 3:00 pm
Location: Naples, FL

Postby bromley » Wed May 31, 2006 7:18 am

Lori,

I agree with you. It's suddenly become a more competitive market - the CRABs have had it pretty easy for the last decade.

Biogen are doing what other companies do in other sectors - buying up promising products or indeed promising companies. There should be more choice as long as the trials provide robust data. The CRABs were the first treatments for this disease and have had their day. The companies have done well out of them and it's time to raise the bar in terms of efficacy.

It wouldn't surprise me if companies such as Biogen bought up products such as Tovaxin and NeuroVax. The bigger companies would have the finances to conduct the trials etc. Innovation often comes from the smaller companies.

Ian
User avatar
bromley
Family Elder
 
Posts: 1887
Joined: Fri Sep 10, 2004 3:00 pm

Postby Brownsfan » Wed May 31, 2006 11:38 am

bromley wrote:Biogen are doing what other companies do in other sectors - buying up promising products or indeed promising companies.... The bigger companies would have the finances to conduct the trials etc.
Ian


Or they could be buying smaller companies on the verge of promising treatments as a way to squash them before they cannibalize the markets of existing drugs.
User avatar
Brownsfan
Family Member
 
Posts: 91
Joined: Thu Aug 25, 2005 3:00 pm


Return to Drug Pipeline

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users